Immutep company info

What does Immutep do?
Immutep (ASX:IMM) is a clinical-stage biotechnology company that is developing novel LAG-3 (lymphocyte-activation gene 3) targeted immunotherapies for cancer and autoimmune diseases. LAG-3 is a cell surface molecule that acts as a checkpoint inhibitor, regulating the activity of T cells, a type of immune cell that plays a critical role in fighting cancer and disease. Immutep's operations are focused on the development and commercialization of its LAG-3 targeted immunotherapies. The company has a portfolio of three clinical-stage and two earlier-stage product candidates. Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3 protein that is currently in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Immutep company media
Company Snapshot

Is Immutep a public or private company?

key
Ownership
Public

How many people does Immutep employ?

people
Employees
45

What sector is Immutep in?

pie chart
Sector
Health Care

Where is the head office for Immutep?

location pin
Head Office
New South Wales, Australia

What year was Immutep founded?

founded flag
Year Founded
2001
What does Immutep specialise in?
/Biotech /Health /Manufacturing /Cancer /Healthcare /Pharmaceutical

What are the products and/or services of Immutep?

Overview of Immutep offerings
Development of LAG-3 targeted immunotherapies for cancer: Immutep is developing a range of LAG-3 targeted immunotherapies for cancer, including eftilagimod alpha (IMP321), a soluble recombinant LAG-3 protein that acts as an agonist of antigen presenting cells (APCs).
Development of T cell receptor (TCR) therapies for cancer: Immutep is developing TCR therapies for cancer, including T cell engaging bispecific antibodies (TEBs) that redirect T cells to tumour cells expressing specific tumour antigens.
Development of bispecific antibody therapies for cancer: Immutep is developing bispecific antibody therapies for cancer, including TEBs and other bispecific antibodies that target different tumour antigens.
Development of combination therapies for cancer: Immutep is developing combination therapies for cancer, which combine LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies with other cancer treatments, such as chemotherapy and radiation therapy.
Licensing of Immutep's technologies to other companies: Immutep licences its technologies to other companies, which allows these companies to develop their own LAG-3 targeted immunotherapies, TCR therapies, and bispecific antibody therapies.
Provision of consulting and support services to other companies developing cancer immunotherapies: Immutep provides consulting and support services to other companies developing cancer immunotherapies, such as advice on preclinical and clinical development, regulatory strategy, and manufacturing.

Who is in the executive team of Immutep?

Immutep leadership team
  • Mr. Marc  Voigt
    Mr. Marc Voigt
    CEO, MD, CFO, Chief Business Officer & Executive Director
  • Ms. Deanne  Miller LLB
    Ms. Deanne Miller LLB
    COO, General Counsel & Joint Company Secretary
  • Dr. Frederic  Triebel M.D., Ph.D.
    Dr. Frederic Triebel M.D., Ph.D.
    Chief Scientific Officer & Executive Director
  • Mr. Christian  Mueller BBA, MSc.
    Mr. Christian Mueller BBA, MSc.
    Senior Vice President of Regulatory & Strategy
  • Mr. Florian D. Vogl M.D., M.Sc., Ph.D.
    Mr. Florian D. Vogl M.D., M.Sc., Ph.D.
    Chief Medical Officer
  • Ms. Indira  Naidu
    Ms. Indira Naidu
    Joint Company Secretary